AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for ...
Hosted on MSN20d
AbbVie to acquire Nimble Therapeutics for $200mAbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...
Hosted on MSN23d
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still BearishAbbVie announced a $200 million deal to acquire Nimble Therapeutics, with additional interim funding and potential development milestone payments. The acquisition includes Nimble’s lead ...
"Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases." "Nimble Therapeutics is committed to transforming ...
This will bring Nimble’s psoriasis and inflammatory bowel disease treatment under AbbVie’s pipeline. AbbVie will acquire Nimble Therapeutics, according to a newly announced agreement. As a result, ...
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback